Related Experiment Video

Updated: Oct 3, 2025

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

7.5K

Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment

Zhenwei Zhang1, Lijun Bai1, Linghui Hou1

  • 1Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China.

European Journal of Medicinal Chemistry
|February 19, 2022
PubMed

Insights

Targeting Bcl-2 proteins for cancer therapy shows promise, but single inhibitors face limitations. Novel apoptosis inducers are being developed to overcome drug resistance and improve cancer treatment efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Apoptosis, or programmed cell death, is crucial for maintaining health and development.
  • Targeting Bcl-2 anti-apoptotic proteins has yielded clinical benefits in cancer treatment.
  • Limitations of current Bcl-2 inhibitors include resistance and limited efficacy.

Purpose of the Study:

  • To review recent advances in novel apoptosis inducers targeting Bcl-2 proteins.
  • To discuss strategies and technologies for overcoming therapeutic limitations.
  • To explore advanced drug design and optimization for Bcl-2-targeted therapies.

Main Methods:

  • Literature review of recent research on apoptosis inducers.
  • Analysis of drug design strategies and optimization technologies.
  • Focus on overcoming limitations of existing Bcl-2 inhibitors.

Main Results:

  • Identification of novel apoptosis-inducing strategies beyond single Bcl-2 inhibition.
  • Exploration of advanced technologies for drug discovery and development.
  • Highlighting approaches to address drug resistance and enhance monotherapy safety.

Conclusions:

  • Novel apoptosis inducers targeting Bcl-2 proteins offer potential to overcome current therapeutic challenges.
  • Advanced drug design and optimization are key to developing more effective cancer therapies.
  • Future research should focus on innovative strategies to enhance the clinical utility of Bcl-2-targeted treatments.
Keywords:
Antibody-drug conjugatesBcl-2 anti-apoptotic proteinsCancer treatmentDegradersDual targeting BH3 mimetics

More Related Videos

Identifying Protein-protein Interaction Sites Using Peptide Arrays07:44

Identifying Protein-protein Interaction Sites Using Peptide Arrays

Published on: November 18, 2014

18.2K
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
711
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K